Media Centre
Latest press releases
-
Imfinzi perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
-
Full Year and Q4 2024 results
-
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer
-
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
-
AstraZeneca plans C$820 million (US$570m) investment in Canada to advance growing global hub and clinical delivery
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
